» Articles » PMID: 20502455

Serum Amyloid A is Elevated in the Serum of Lung Cancer Patients with Poor Prognosis

Overview
Journal Br J Cancer
Specialty Oncology
Date 2010 May 27
PMID 20502455
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Lung cancer is known as the top cancer killer in most developed countries. However, there is currently no promising diagnostic or prognostic biomarker for lung cancer. This study aims to discover non-invasive differential markers in the serum of lung cancer patients, to determine the protein identity of the candidate biomarker(s), and to investigate any clinical implication of the biomarker(s) concerned.

Methods: Blood specimens were collected from 154 pre-operative patients with lung cancer and 35 healthy blood donors with no evidence of lung cancer. Fractionated serum samples were processed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (MS). Candidate biomarker was identified using sodium dodecyl sulphate polyacrylamide gel electrophoresis and tryptic digestion followed by tandem MS fragmentation analysis, which was subsequently validated with immunoassay.

Results: A differential protein with m/z 11.6 kDa was detected and identified as an isoform of human serum amyloid A (SAA). It was significantly increased by 1822% in lung cancer patients when compared with the healthy controls, which gave an area under the receiver operator characteristic curve of 0.88. In addition, the protein was also significantly elevated by 77% in lung cancer patients with survival <5 years when compared with patients with survival > or =5 years.

Conclusion: There are several functions of the SAA protein, described in the context of inflammation, that are compatible with the mechanism of tumour invasion and metastasis. Our study not only detected increased SAA level in the serum of lung cancer patients but also identified that elevated SAA level may be a non-invasive biomarker useful for the prediction of lung cancer prognosis.

Citing Articles

Multi-omics with dynamic network biomarker algorithm prefigures organ-specific metastasis of lung adenocarcinoma.

Zhang X, Xiao K, Wen Y, Wu F, Gao G, Chen L Nat Commun. 2024; 15(1):9855.

PMID: 39543109 PMC: 11564768. DOI: 10.1038/s41467-024-53849-3.


A comparative study of ProGRP and CEA as serological markers in small cell lung cancer treatment.

Yu M, Wang P Discov Oncol. 2024; 15(1):485.

PMID: 39331166 PMC: 11436604. DOI: 10.1007/s12672-024-01323-3.


ACE Phenotyping in Human Blood and Tissues: Revelation of ACE Outliers and Sex Differences in ACE Sialylation.

Enyedi E, Petukhov P, Kozuch A, Dudek S, Toth A, Fagyas M Biomedicines. 2024; 12(5).

PMID: 38790902 PMC: 11117852. DOI: 10.3390/biomedicines12050940.


Clinical Manifestations and Management of Fibrotic Pulmonary Sarcoidosis.

Kim J, Gupta R J Clin Med. 2024; 13(1).

PMID: 38202248 PMC: 10780222. DOI: 10.3390/jcm13010241.


Diagnostic and Prognostic Significance of Serum Biomarkers - Serum Amyloid A and CYFRA 21-1 in Lung Cancer.

Dhanurdhar Y, Jagaty S, Subhankar S, Behera D Int J Appl Basic Med Res. 2023; 13(2):89-94.

PMID: 37614836 PMC: 10443456. DOI: 10.4103/ijabmr.ijabmr_639_22.


References
1.
Gamez-Pozo A, Sanchez-Navarro I, Nistal M, Calvo E, Madero R, Diaz E . MALDI profiling of human lung cancer subtypes. PLoS One. 2009; 4(11):e7731. PMC: 2767501. DOI: 10.1371/journal.pone.0007731. View

2.
Cho W, Yip T, Ngan R, Yip T, Podust V, Yip C . ProteinChip array profiling for identification of disease- and chemotherapy-associated biomarkers of nasopharyngeal carcinoma. Clin Chem. 2007; 53(2):241-50. DOI: 10.1373/clinchem.2005.065805. View

3.
Cohen A, Geva-Zatorsky N, Eden E, Frenkel-Morgenstern M, Issaeva I, Sigal A . Dynamic proteomics of individual cancer cells in response to a drug. Science. 2008; 322(5907):1511-6. DOI: 10.1126/science.1160165. View

4.
Vermaat J, van der Tweel I, Mehra N, Sleijfer S, Haanen J, Roodhart J . Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models. Ann Oncol. 2009; 21(7):1472-1481. DOI: 10.1093/annonc/mdp559. View

5.
Cho W, Yip T, Yip C, Yip V, Thulasiraman V, Ngan R . Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res. 2004; 10(1 Pt 1):43-52. DOI: 10.1158/1078-0432.ccr-0413-3. View